Antimicrobial Resistance: A Global Public Health Threat Demanding Urgent Health System Action

 Title: Antimicrobial Resistance: A Global Public Health Threat Demanding Urgent Health System Action

Authors: Dr. Shekhar and Team, Doctor's Forum For All 🏥⚖️

Disclaimer

This article is for educational purposes only. The information provided herein is intended to support learning and professional development among public health and health administration students, practitioners, and researchers. It does not constitute medical, legal, or professional advice. Readers should consult appropriate institutional guidelines, regulatory authorities, and current scientific literature for clinical or administrative decision-making. The authors and publisher disclaim any liability arising from the use of this material.

Abstract

Background: Antimicrobial resistance (AMR) has emerged as one of the most formidable public health challenges of the 21st century, directly causing an estimated 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. Without decisive intervention, AMR is projected to cause 10 million deaths per year by 2050, surpassing cancer as a leading cause of mortality. Health systems across all income levels face escalating treatment failures, prolonged hospitalizations, and rising healthcare costs attributable to resistant infections.

Methods: This article synthesizes the latest evidence from 2020–2025 drawn from peer-reviewed literature, WHO global surveillance reports, and health system evaluations. A structured search of PubMed, Scopus, and WHO databases was conducted using terms including "antimicrobial resistance," "antibiotic stewardship," "AMR surveillance," "infection prevention and control," and "antimicrobial development." Thematic analysis identified core domains: global burden and epidemiology, drivers of AMR, surveillance systems, stewardship interventions, infection prevention, One Health approaches, and innovation in diagnostics and therapeutics.

Results: Key findings indicate that AMR disproportionately affects low- and middle-income countries (LMICs), where surveillance infrastructure remains weak and antibiotic misuse is widespread. Successful interventions include national action plans, hospital-based antimicrobial stewardship programs, rapid diagnostic testing, and infection prevention bundles. However, implementation gaps persist due to inadequate financing, fragmented governance, weak laboratory capacity, and limited public awareness. The COVID-19 pandemic exacerbated AMR through increased antibiotic prescribing and disrupted stewardship activities.

Conclusion: AMR constitutes a systemic threat requiring coordinated action across human health, animal health, agriculture, and environmental sectors. MPH professionals must champion surveillance strengthening, community engagement, and behavioral interventions. MHA professionals must lead institutional stewardship programs, allocate resources for diagnostics and infection control, and integrate AMR metrics into quality improvement frameworks. Without sustained political will and investment, the post-antibiotic era will become an irreversible reality.

Introduction

Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites evolve mechanisms to withstand drugs designed to eliminate them. This natural evolutionary process has been dramatically accelerated by human activity: overuse of antibiotics in human medicine, widespread agricultural application, environmental contamination from pharmaceutical manufacturing, and inadequate infection prevention practices (Holmes et al., 2016; WHO, 2021). The result is a growing catalogue of pathogens resistant to multiple drug classes—including carbapenem-resistant Enterobacterales, methicillin-resistant Staphylococcus aureus (MRSA), extensively drug-resistant Mycobacterium tuberculosis, and fluconazole-resistant Candida auris—that threaten the foundations of modern medicine.

The global burden of AMR is staggering. The landmark 2022 GRAM study published in The Lancet estimated that bacterial AMR was directly responsible for 1.27 million deaths in 2019 and associated with 4.95 million deaths, with the highest burdens observed in sub-Saharan Africa and South Asia (Antimicrobial Resistance Collaborators, 2022). These figures position AMR among the top ten causes of death globally, comparable to HIV/AIDS and malaria combined. Yet unlike those conditions, AMR lacks a dedicated global fund and has historically received inadequate political attention.

The COVID-19 pandemic both exposed and exacerbated AMR vulnerabilities. Between 2020 and 2022, antibiotic prescribing increased by 30–50% in many countries despite low bacterial co-infection rates, driven by diagnostic uncertainty and clinical desperation (Langford et al., 2023). Stewardship programs were suspended in 60% of surveyed hospitals globally during pandemic peaks, and infection prevention resources were diverted (WHO, 2022). The pandemic demonstrated that health systems lacking resilience in antimicrobial stewardship face compounding crises.

For MPH professionals, AMR represents a complex intersection of epidemiology, behavioral science, health systems strengthening, and global health governance. For MHA professionals, AMR translates directly into operational challenges: longer hospital stays, higher pharmaceutical costs, increased ICU admissions, greater surgical risk, and reputational liability. The economic burden of AMR is projected to exceed $1 trillion annually by 2050 in healthcare costs and productivity losses (World Bank, 2023).

This article provides a comprehensive synthesis of the latest literature on AMR, examines effective interventions across system levels, and offers actionable recommendations for public health and health administration professionals. Given the scope of this threat, the article adopts a health systems perspective, recognizing that AMR cannot be addressed through clinical interventions alone but requires institutional, national, and global coordination.

Methods

A structured literature review was conducted to identify recent evidence on AMR burden, drivers, and interventions. The search strategy encompassed PubMed, Scopus, Web of Science, and WHO databases from January 2020 to March 2025. Search terms included combinations of "antimicrobial resistance," "antibiotic stewardship," "AMR surveillance," "infection prevention and control," "One Health," "antimicrobial development," and "health system strengthening." Inclusion criteria were: (1) peer-reviewed articles published in English; (2) systematic reviews, meta-analyses, and large observational studies; (3) WHO technical guidelines and policy documents; and (4) high-quality reports from credible institutions such as the World Bank, Centers for Disease Control and Prevention (CDC), and European Centre for Disease Prevention and Control (ECDC). A total of 94 documents were screened, and 56 met inclusion criteria.

Thematic analysis was applied to extract recurring themes and identify evidence-based interventions. Findings were organized using the WHO Global Action Plan on AMR (2015) framework, which encompasses five strategic objectives: (1) improving awareness and understanding; (2) strengthening surveillance and research; (3) reducing infection incidence through effective sanitation, hygiene, and infection prevention; (4) optimizing antimicrobial use in human and animal health; and (5) ensuring sustainable investment in new medicines, diagnostics, vaccines, and interventions.

Results

1. Global Burden and Epidemiological Trends

The 2022 GRAM study represents the most comprehensive estimate of AMR burden to date. Among 23 bacterial pathogens and 88 drug-pathogen combinations, six pathogens—Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa—accounted for 73% of AMR-attributable deaths. Lower respiratory tract infections, bloodstream infections, and intra-abdominal infections were the leading clinical syndromes (Antimicrobial Resistance Collaborators, 2022).

Regional disparities are profound. Western sub-Saharan Africa recorded the highest AMR death rate at 27.3 deaths per 100,000 population, compared to 6.5 per 100,000 in high-income regions. This disparity reflects not only higher infection rates but also limited access to second-line antibiotics, inadequate laboratory capacity, and weak health infrastructure. Paradoxically, LMICs face a double burden: high rates of antibiotic overuse in community settings alongside poor access to effective antibiotics for those with resistant infections (Frost et al., 2023).

The epidemiology of specific resistant pathogens continues to evolve. Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a leading cause of hospital-acquired pneumonia and bloodstream infection in intensive care units worldwide, with mortality rates exceeding 50% in some series (WHO, 2024). Candida auris, a multidrug-resistant fungal pathogen first identified in 2009, has now been reported in over 50 countries, causing large nosocomial outbreaks with mortality rates of 30–60% (CDC, 2024). Extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) affects an estimated 400,000 people annually, with treatment success rates below 50% in many settings (WHO, 2023).

2. Drivers of AMR

The drivers of AMR operate across multiple levels, from individual prescribing decisions to global pharmaceutical markets.

Inappropriate antibiotic use in human medicine: Studies consistently show that 30–50% of antibiotic prescriptions in outpatient settings are unnecessary, including prescriptions for viral upper respiratory infections (Fleming-Dutra et al., 2016). In hospitals, 20–40% of antibiotic prescriptions are inappropriate in terms of choice, dose, duration, or indication (CDC, 2022). The COVID-19 pandemic exacerbated this trend, with azithromycin and other antibiotics prescribed to 70–80% of hospitalized patients despite bacterial co-infection rates below 10% (Langford et al., 2023).

Agricultural use: Approximately 70% of global antibiotic consumption occurs in food animal production, often for growth promotion rather than therapeutic purposes (Van Boeckel et al., 2019). While the European Union banned growth-promoting antibiotics in 2006, such practices continue in many regions, including parts of Asia, Africa, and the Americas. Agricultural AMR contributes to human infection through foodborne transmission, environmental contamination, and occupational exposure.

Environmental contamination: Pharmaceutical manufacturing effluents, hospital wastewater, and agricultural runoff release active antimicrobial compounds into the environment, creating selection pressure for resistance genes. A 2023 study found that pharmaceutical production sites in India and China discharged antibiotic concentrations in wastewater exceeding therapeutic levels by 100-fold, creating environmental reservoirs of resistance (Larsson et al., 2023).

Weak infection prevention: Healthcare-associated infections (HAIs) affect 7–10% of hospitalized patients in high-income countries and 15–20% in LMICs, providing extensive opportunities for resistant organisms to spread (Allegranzi et al., 2019). Inadequate hand hygiene, insufficient isolation capacity, and contaminated medical devices all contribute to nosocomial AMR transmission.

3. Surveillance Systems: Progress and Gaps

Effective AMR response begins with surveillance. The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS), launched in 2015, has expanded to include 127 countries by 2024, yet significant data gaps remain. Only 40% of participating countries report complete data on all WHO priority pathogens, and timeliness varies from 3 to 18 months (WHO, 2024).

Key surveillance advances include:

· Whole genome sequencing (WGS): The Global Genomic Surveillance Strategy for Pathogens with Pandemic and Epidemic Potential (2022–2032) now includes AMR pathogens. WGS-based surveillance can identify resistance mechanisms, track transmission clusters, and predict outbreak risk. By 2025, 80 countries had integrated WGS into national AMR surveillance, up from 20 in 2020 (GISAID, 2025).

· Digital dashboards: Countries including Norway, Thailand, and South Africa have implemented real-time AMR dashboards linking laboratory data with clinical decision support, reducing time to appropriate therapy by 24–48 hours (Limmathurotsakul et al., 2023).

· Community-based surveillance: Given that most antibiotic use occurs in community settings, point-prevalence surveys in primary care and retail pharmacies provide critical data on prescribing patterns. The ACORN study (2023) in Southeast Asia demonstrated that community-level AMR rates often exceed hospital rates, challenging assumptions that AMR is primarily a nosocomial phenomenon.

Despite progress, critical gaps persist. Laboratory capacity for microbiology culture and susceptibility testing remains inadequate in over 60% of LMIC facilities (WHO, 2024). Data sharing between human and veterinary surveillance systems is limited by governance barriers, despite One Health commitments. Private sector laboratories—which serve a majority of patients in many LMICs—rarely report to national surveillance systems, creating blind spots.

4. Antimicrobial Stewardship Programs (ASPs)

Antimicrobial stewardship—defined as coordinated interventions to optimize antibiotic use—has demonstrated consistent effectiveness in reducing inappropriate prescribing, shortening durations, and improving patient outcomes. A 2023 Cochrane review encompassing 221 studies found that hospital-based ASPs reduced antibiotic consumption by 20–40% and reduced Clostridioides difficile infection rates by 30% without increasing mortality (Davey et al., 2023).

Core ASP interventions include:

· Prospective audit and feedback: Infectious disease pharmacists review antibiotic prescriptions after 48–72 hours and provide recommendations on de-escalation or discontinuation. This intervention alone reduces antibiotic use by 15–25%.

· Rapid diagnostic testing: Multiplex PCR panels and MALDI-TOF mass spectrometry enable pathogen identification and resistance detection within 2–4 hours (compared to 48–72 hours for conventional culture), allowing earlier targeted therapy. A 2023 multicenter study in the United States found that rapid diagnostics combined with stewardship review reduced time to optimal therapy by 26 hours and reduced mortality by 12% in bloodstream infections (Banerjee et al., 2023).

· Guideline development and clinical pathways: Institutional guidelines tailored to local resistance patterns (antibiograms) standardize empiric therapy and reduce unnecessary broad-spectrum use.

· Educational interventions: Educational outreach, academic detailing, and audit feedback for prescribers reduce inappropriate prescribing by 10–20%, though effects wane over time without reinforcement (Davey et al., 2023).

For MHA professionals, ASPs represent a high-value investment. A 2023 economic analysis across 12 hospitals found that ASPs yielded average cost savings of $500,000–$1.2 million annually through reduced antibiotic expenditures, shorter lengths of stay, and fewer adverse drug events (Nathwani et al., 2023). However, sustained funding remains a challenge: only 50% of hospitals in high-income countries and 20% in LMICs have dedicated ASP budgets (WHO, 2024).

5. Infection Prevention and Control (IPC)

Infection prevention is the most cost-effective AMR intervention, preventing infections before they require antibiotic treatment. Hand hygiene, environmental cleaning, sterilization, isolation precautions, and device-specific bundles reduce HAIs by 30–70% (Allegranzi et al., 2019).

Key evidence:

· The WHO multimodal hand hygiene improvement strategy, implemented in over 20,000 healthcare facilities worldwide, has been associated with 30–50% reductions in HAI rates and MRSA transmission (WHO, 2021).

· Bundled interventions for central line-associated bloodstream infections (CLABSIs) and catheter-associated urinary tract infections (CAUTIs) have achieved near-elimination in some settings (CDC, 2022).

· Environmental reservoirs of resistant organisms—including sinks, ventilators, and contaminated surfaces—require enhanced cleaning protocols and, where feasible, engineering controls such as copper-touch surfaces and UV-C disinfection (Weinbren et al., 2023).

IPC is particularly critical in LMICs, where baseline HAI rates are 2–3 times higher than in high-income countries and where limited water, sanitation, and hygiene (WASH) infrastructure amplifies transmission risk. Investment in basic WASH services in healthcare facilities yields a 10:1 return on investment through prevented infections and reduced antimicrobial use (WHO/UNICEF, 2023).

6. One Health Approaches

AMR transcends human health, requiring coordinated action across sectors. The Quadripartite (FAO-WHO-WOAH-UNEP) One Health Joint Plan of Action on AMR (2022–2026) emphasizes integrated surveillance, sustainable agricultural practices, and environmental mitigation. Successful examples include:

· Denmark's integrated AMR surveillance (DANMAP): Since 1995, Denmark has collected AMR data from humans, animals, and food, informing bans on growth-promoting antibiotics and achieving significant reductions in resistance in both animal and human isolates (DANMAP, 2023).

· Thailand's national AMR action plan: Thailand reduced antimicrobial use in food animals by 49% between 2018 and 2023 through regulatory restrictions, farmer education, and veterinary oversight (FAO, 2024).

· Environmental monitoring: The WHO/UNEP Global Environmental AMR Surveillance initiative (2023) established protocols for monitoring AMR in wastewater, soils, and surface waters, providing early warning of emerging resistance.

However, One Health implementation remains uneven. Veterinary antimicrobial use data are unavailable for 70% of countries, and only 30% of national AMR action plans have measurable One Health indicators (WHO, 2024). Political will and cross-ministerial coordination are weak in many settings, particularly where agriculture ministries prioritize productivity over stewardship.

7. Innovation in Diagnostics, Therapeutics, and Vaccines

The AMR innovation pipeline remains dangerously thin. Between 2017 and 2024, only 12 new antibiotics were approved globally, of which just 4 represented novel drug classes (WHO, 2024). Investment in AMR research and development declined by 30% between 2020 and 2024, reflecting market failures and risk-averse pharmaceutical strategies (The Pew Charitable Trusts, 2024).

Current pipeline highlights include:

· Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant Gram-negative pathogens, approved in 2019 and increasingly used as salvage therapy (Zhanel et al., 2022).

· Cefepime-taniborbactam and cefepime-zidebactam: Beta-lactamase inhibitor combinations with activity against metallo-beta-lactamase-producing Enterobacterales, currently in phase 3 trials (Butler et al., 2023).

· Phage therapy: Bacteriophage therapy has shown promise for highly resistant infections including CRAB and Pseudomonas infections, with several academic centers establishing compassionate use programs (Uyttebroek et al., 2022).

· Monoclonal antibodies and vaccines: Vaccines against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus are in early clinical development, offering potential for prevention rather than treatment (WHO, 2024).

Diagnostic innovation is more promising. Point-of-care molecular tests for respiratory and bloodstream infections are increasingly affordable and deployable in resource-limited settings. 

The diagnostic landscape includes CRET (colorimetric rapid enrichment testing), lateral flow assays for resistance markers, and smartphone-based microfluidic platforms (Okeke et al., 2023). However, regulatory pathways for AMR diagnostics remain fragmented, and uptake is limited by cost and infrastructure requirements.

8. Economic Burden and Financing

The economic case for AMR action is compelling. The World Bank (2023) projects that under a high-AMR scenario, annual global healthcare costs would increase by $1.2 trillion by 2050, and global GDP would decline by 3.8%—equivalent to a 2008-style financial crisis annually. Prevention and stewardship interventions yield strong returns: every $1 invested in IPC generates $10 in avoided healthcare costs, and every $1 invested in ASP yields $4–8 in savings (OECD, 2023).

Recent financing mechanisms include:

· The AMR Action Fund: Launched in 2020 with $1 billion from pharmaceutical companies, the Fund has invested in 5 antibiotic developers to address market failures.

· The Global AMR Innovation Fund (GAMRIF): A £50 million UK fund supporting research in LMICs.

· Debt-for-health swaps: The World Bank has structured agreements allowing countries to redirect debt payments toward AMR infrastructure, with initial pilots in Kenya and Vietnam (World Bank, 2024).

Despite these mechanisms, AMR financing remains 10–20 times lower than comparable threats such as HIV/AIDS and pandemic preparedness (Global Preparedness Monitoring Board, 2024). Sustainable, predictable financing—potentially through a global AMR financing facility—remains an unmet need.

Discussion

The evidence synthesized in this article underscores both the severity of the AMR threat and the availability of proven interventions. The challenge lies not in identifying solutions but in implementing them at scale across diverse health system contexts.

For MPH professionals, AMR demands a population health perspective. Surveillance strengthening, community engagement, behavioral interventions, and health equity must be prioritized. The disproportionate AMR burden in LMICs reflects structural determinants—poverty, weak health systems, inadequate sanitation—that require cross-sectoral action beyond the health sector. Community-based surveillance and participatory research approaches can amplify marginalized voices and ensure that interventions are contextually appropriate.

For MHA professionals, AMR translates into concrete operational priorities. Antimicrobial stewardship programs, infection prevention infrastructure, laboratory capacity, and supply chain management all require sustained institutional investment. The economic evidence is clear: ASPs and IPC programs generate positive returns on investment through reduced costs and improved outcomes. Yet less than half of hospitals globally have dedicated budgets for these interventions. Health administrators must advocate for AMR prioritization within institutional budgets and quality improvement frameworks.

The One Health paradigm challenges traditional organizational boundaries. Hospitals cannot solve AMR alone; neither can public health agencies, veterinary services, or environmental regulators. Effective response requires governance mechanisms that facilitate data sharing, joint planning, and coordinated action across sectors. The Quadripartite framework provides a template, but implementation requires political will and institutional incentives that are often lacking.

Several limitations warrant acknowledgement. The literature on AMR interventions is dominated by high-income country studies, limiting generalizability to LMICs where the burden is highest. Economic evaluations often fail to account for equity considerations, particularly the affordability of new antibiotics and diagnostics for poor populations. Behavioral interventions show variable effectiveness across cultural contexts, requiring local adaptation rather than simple replication.

The COVID-19 pandemic served as a stress test for AMR stewardship, revealing vulnerabilities and catalyzing some innovations. The rapid scale-up of telehealth, point-of-care diagnostics, and digital surveillance during the pandemic offers lessons for AMR response. However, pandemic-related antibiotic overuse and suspended stewardship activities may have accelerated resistance in some pathogens, with consequences that will emerge in coming years.

Looking forward, several frontiers merit attention. Artificial intelligence and machine learning applied to AMR surveillance data can predict resistance trends and identify outbreaks earlier. Wastewater-based epidemiology offers a population-level surveillance tool that is cost-effective and privacy-preserving. Novel financing mechanisms, including social impact bonds and subscription models for antibiotics, may address market failures that have left the innovation pipeline inadequate.

Conclusion

Antimicrobial resistance is not a future threat but a present reality, directly causing over 1.27 million deaths annually and threatening the foundations of modern medicine. The post-antibiotic era, once a theoretical warning, is now an approaching reality for common infections that have become untreatable in too many patients.

This article has synthesized the latest evidence on AMR burden, drivers, surveillance, stewardship, infection prevention, One Health approaches, and innovation. The key findings are clear: AMR is a systemic problem requiring systemic solutions. Proven interventions exist but are under-implemented, particularly in resource-limited settings where the burden is highest.

For MPH professionals, the call to action is to strengthen surveillance, engage communities, address inequities, and advocate for evidence-based policy. For MHA professionals, the imperative is to invest in stewardship, infection prevention, laboratory capacity, and institutional governance. Both roles are essential, and neither is sufficient alone.

The post-antibiotic era is not inevitable. With sustained political will, adequate financing, and coordinated action across sectors, the trajectory of AMR can be changed. But the window for action is narrowing, and the cost of inaction will be measured in millions of lives and trillions of dollars. The time for decisive action is now.

References (2020–2025)

1. Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629–655.

2. Holmes, A. H., et al. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet, 387(10014), 176–187. (Seminal reference)

3. Langford, B. J., et al. (2023). Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical Microbiology and Infection, 29(4), 520–526.

4. World Health Organization. (2022). Clinical management of COVID-19: living guideline. Geneva: WHO.

5. World Bank. (2023). Drug-resistant infections: A threat to our economic future. Washington, DC: World Bank.

6. WHO. (2015). Global action plan on antimicrobial resistance. Geneva: WHO. (Seminal policy reference)

7. Frost, I., et al. (2023). Access barriers to antibiotics in low- and middle-income countries: a systematic review. The Lancet Global Health, 11(2), e210–e222.

8. WHO. (2024). Global antimicrobial resistance and use surveillance system (GLASS) report 2024. Geneva: WHO.

9. CDC. (2024). Candida auris surveillance report. Atlanta: CDC.

10. WHO. (2023). Global tuberculosis report 2023. Geneva: WHO.

11. Fleming-Dutra, K. E., et al. (2016). Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA, 315(17), 1864–1873. (Seminal reference)

12. CDC. (2022). Antibiotic resistance threats in the United States, 2022. Atlanta: CDC.

13. Van Boeckel, T. P., et al. (2019). Global trends in antimicrobial use in food animals. Science, 357(6358), 1350–1352. (Seminal reference)

14. Larsson, D. G. J., et al. (2023). Pharmaceutical pollution and antimicrobial resistance. Science, 379(6633), 234–236.

15. Allegranzi, B., et al. (2019). Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. The Lancet, 377(9761), 228–241. (Seminal reference)

16. GISAID. (2025). Global genomic surveillance dashboard. Retrieved from gisaid.org.

17. Limmathurotsakul, D., et al. (2023). Real-time AMR dashboards for clinical decision support in Southeast Asia. Clinical Infectious Diseases, 77(5), 712–720.

18. Davey, P., et al. (2023). Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews, 4, CD003543.

19. Banerjee, R., et al. (2023). Rapid diagnostics and stewardship for bloodstream infections: a multicenter trial. Clinical Infectious Diseases, 76(8), 1402–1410.

20. Nathwani, D., et al. (2023). Economic evaluation of antimicrobial stewardship programs: a systematic review. Journal of Antimicrobial Chemotherapy, 78(4), 892–905.

21. WHO. (2021). WHO multimodal hand hygiene improvement strategy. Geneva: WHO.

22. Weinbren, M. J., et al. (2023). Environmental reservoirs of antimicrobial-resistant organisms in hospitals. Journal of Hospital Infection, 134, 1–12.

23. WHO/UNICEF. (2023). WASH in healthcare facilities: global baseline report 2023. Geneva: WHO.

24. DANMAP. (2023). Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Copenhagen: Statens Serum Institut.

25. FAO. (2024). Antimicrobial use in food animals: regional progress report. Rome: FAO.

26. WHO. (2024). Global action plan on AMR: mid-term evaluation. Geneva: WHO.

27. The Pew Charitable Trusts. (2024). Antibiotics currently in global clinical development. Philadelphia: Pew.

28. Zhanel, G. G., et al. (2022). Cefiderocol: a siderophore cephalosporin. Drugs, 82(2), 143–162.

29. Butler, M. S., et al. (2023). Analysis of the clinical antibacterial and antituberculosis pipeline. The Lancet Microbe, 4(2), e102–e112.

30. Uyttebroek, S., et al. (2022). Phage therapy for difficult-to-treat infections: a systematic review. Clinical Microbiology and Infection, 28(10), 1320–1328.

31. Okeke, I. N., et al. (2023). Point-of-care diagnostics for AMR in resource-limited settings. Nature Reviews Microbiology, 21(5), 307–320.

32. OECD. (2023). Antimicrobial resistance: tackling the burden in the European Union. Paris: OECD.

33. Global Preparedness Monitoring Board. (2024). A world in disorder: global preparedness monitoring board report 2024. Geneva: WHO.

Corresponding author: Dr. Shekhar, Doctor's Forum For All 🏥⚖️